James Bristol
Chairman at ETERNA THERAPEUTICS INC.
Net worth: 522 900 $ as of 2024-05-30
James Bristol active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ERASCA, INC. | Director/Board Member | 2018-05-31 | - |
| Independent Dir/Board Member | 2018-05-31 | - | |
| ETERNA THERAPEUTICS INC. | Independent Dir/Board Member | 2023-10-29 | - |
| Chairman | 2023-12-18 | - | |
| Director/Board Member | 2023-10-29 | 2023-12-18 | |
Protypia, Inc.
 Protypia, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Inotiv, Inc., Protypia, Inc. provides targeted tissue-based protein and peptide mass spectrometry solutions. The company is based in Nashville, TN. The company was founded in 2017 by Daniel C. Liebler. Daniel C. Liebler has been the CEO since 2017. Protypia was acquired by Inotiv, Inc. on July 07, 2022 for $11 million. | Director/Board Member | - | - |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Consultant / Advisor | 2008-12-31 | - |
| Gordon Research Conferences | Corporate Officer/Principal | - | - |
Deciphera Pharmaceuticals LLC
 Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Chairman | 2009-03-24 | - |
Career history of James Bristol
Former positions of James Bristol
| Companies | Position | Start | End |
|---|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Director/Board Member | 2023-08-02 | 2024-06-10 |
| Chairman | 2015-01-31 | 2023-08-02 | |
| Independent Dir/Board Member | 2007-07-31 | 2024-06-10 | |
Sudo Biosciences, Inc.
 Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | Director/Board Member | 2021-05-31 | 2023-11-30 |
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Director/Board Member | 2010-12-31 | 2020-12-31 |
| ░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░ ░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | - | ░░░░░░░░░░ |
| ░░░░░░ ░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of James Bristol
| University of New Hampshire | Doctorate Degree |
| Bates College | Undergraduate Degree |
Statistics
International
| United States | 18 |
Operational
| Director/Board Member | 7 |
| Corporate Officer/Principal | 5 |
| Independent Dir/Board Member | 4 |
Sectoral
| Health Technology | 10 |
| Finance | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| ERASCA, INC. | Health Technology |
| ETERNA THERAPEUTICS INC. | Health Technology |
| Private companies | 12 |
|---|---|
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Finance |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
Pfizer (St. Louis)
 Pfizer (St. Louis) BiotechnologyHealth Technology Part of Pfizer Inc., Pfizer (St. Louis) is a company that provides research services in prescription medicines for humans and animals. The company is based in Chesterfield, MO. | Health Technology |
Warner-Lambert Co.
 Warner-Lambert Co. Pharmaceuticals: MajorHealth Technology Warner-Lambert Co. used to manufacture and market pharmaceuticals, consumer health care products & confectionery. Its pharmaceutical products were ethical pharmaceuticals, biological products and hard-gelatin capsules. Its consumer health products were a wide range of products like oral care mouthwash/dental rinses, toothpaste, effervescent denture cleaning tablets, upper respiratory cold & sinus preparations, antihistamines, allergy products and cough syrups/suppressants. The company was headquartered in Morris Plains, NJ. | Health Technology |
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Health Technology |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |
| The Polycystic Kidney Disease Research Foundation | |
Deciphera Pharmaceuticals, Inc.
 Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
| Gordon Research Conferences | |
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Finance |
Protypia, Inc.
Protypia, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Inotiv, Inc., Protypia, Inc. provides targeted tissue-based protein and peptide mass spectrometry solutions. The company is based in Nashville, TN. The company was founded in 2017 by Daniel C. Liebler. Daniel C. Liebler has been the CEO since 2017. Protypia was acquired by Inotiv, Inc. on July 07, 2022 for $11 million. | Commercial Services |
Sudo Biosciences, Inc.
Sudo Biosciences, Inc. Information Technology ServicesTechnology Services Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd. | Technology Services |
- Stock Market
- Insiders
- James Bristol
- Experience
